Companies

INSM · Biotech

INSMED Inc

SEC company filings

Reported cash

USD 396,563,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · FDA target date

ARIKAYCE · Mycobacterium avium complex · January 28, 2027

Mycobacterium avium complex (MAC) lung disease

Announced Oct 29, 2026

Official announcement
Source wording

In September 2026, the U.S. Food and Drug Administration (FDA) accepted Insmed’s Supplemental New Drug Application (sNDA) for review of ARIKAYCE for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen. The FDA granted Priority Review to the sNDA and set a target action date of January 28, 2027, under the Prescription Drug User Fee Act (PDUFA).

Drug pipeline

0 programs · 0 verified studies

No verified studies linked yet.

56 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.